Antibodies directed to tumor necrosis factor
US7285269B2 · kind B2 · utility
68Cited by
188References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 2, 2003 |
| Grant date | Oct 23, 2007 |
| Priority date | — |
| Expiry date | Apr 17, 2024 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Antibodies directed to the antigen TNFα and uses of such antibodies. In particular, fully human monoclonal antibodies directed to the antigen TNFα. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.